Helix BioPharma (TSE:HBP) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Helix BioPharma Corp. has received a U.S. patent for its innovative L-DOS47 platform, which targets tumors with high CEACAM6 expression, potentially enhancing cancer treatment outcomes. This development strengthens Helix’s position in the oncology market, offering new hope for patients with hard-to-treat cancers.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.